Evidence map›Paper›PMID 41768256›Full record

ArticleFrontiers in oncology2026

Uncovering potential molecular biomarkers for cancer-associated secondary lymphedema through integrated analyses of RNA-sequencing, machine learning, and clinical data.

Hao Dong, Jianliang Miao, Zhong Liu, Yuguang Sun, Peilin Li, Song Xia, Wenbin Shen

Erratum issuedAbstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Hao Dong *Department of Lymphatic Surgery, Capital Medical University Affiliated Beijing Shijitan Hospital, Beijing, China.
Jianliang Miao *First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China.
Zhong LiuDepartment of Lymphatic Surgery, Capital Medical University Affiliated Beijing Shijitan Hospital, Beijing, China.
Yuguang SunDepartment of Lymphatic Surgery, Capital Medical University Affiliated Beijing Shijitan Hospital, Beijing, China.
Peilin LiDepartment of Lymphatic Surgery, Capital Medical University Affiliated Beijing Shijitan Hospital, Beijing, China.
Song XiaDepartment of Lymphatic Surgery, Capital Medical University Affiliated Beijing Shijitan Hospital, Beijing, China.
Wenbin ShenDepartment of Lymphatic Surgery, Capital Medical University Affiliated Beijing Shijitan Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cancer-associated secondary lymphedema (CASL) commonly occurs after tumor-related lymph node dissection and radiotherapy. Nevertheless, the mechanisms of CASL remain unclear, and there are no specific molecular markers for its diagnosis and treatment. Methods: In this study, RNA sequencing was performed on adipose tissues from 10 normal controls and 40 patients with CASL. Differentially expressed genes were screened using two machine learning algorithms to identify potential molecular markers for CASL. Subsequently, seven machine learning algorithms were employed to develop predictive models based on the identified markers. The contribution of each feature to the predictive outcomes was interpreted using Shapley additive explanation (SHAP). Immune cell infiltration was profiled through CIBERSORT and MCP-counter algorithms, and single-cell RNA sequencing (scRNA-seq) data were integrated to explore interactions between characteristic genes and immune cell subpopulations. Furthermore, associations between characteristic genes and clinical parameters were also assessed. Results: IL2RG, HOXD10, and TSPAN1 were identified as potential biomarkers of CASL. Diagnostic models built on these three genes showed excellent performance. Functional enrichment analysis suggested that the dysregulation of cytokine-cytokine receptor interactions and immune pathways underlies the pathological progression of CASL. In addition, immune infiltration analysis indicated that T cell and macrophage infiltration were intricately involved in CASL progression. Intriguingly, single-cell transcriptomic analysis further revealed elevated expression of IL2RG, HOXD10, and TSPAN1 in T cell subsets. Finally, RT-qPCR validated that these genes were expressed at higher levels in CASL tissues than in normal tissues. Moreover, IL2RG expression was strongly associated with clinical parameters. Conclusions: This study identified IL2RG, HOXD10, and TSPAN1 as novel potential molecular markers for CASL, providing valuable biological evidence for the diagnosis and intervention of CASL.

Indexed as

immune infiltrationmachine learningScRNAsecondary lymphedemaSHAP

Identifiers

PMID41768256
PMCPMC12945810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.